Le Lézard
Classified in: Health, Science and technology, Covid-19 virus

Worldwide Transfection Reagents and Equipment Industry to 2026 - Technological Advancements in Transfection are Driving Growth - ResearchAndMarkets.com


The "Transfection Reagents and Equipment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.

The major factors that are driving the market growth include technological advancements in transfection, an increase in R&D expenditure and research activities by pharmaceutical and biotech companies, and a rise in demand for synthetic genes.

Companies Mentioned

Key Market Trends

Pharmaceutical & Biotechnology Companies are Expected to Hold a Significant Share in the End User Segment

The rapid progress of cell and gene therapies through clinical development is fueling the demand for late-stage clinical and commercial manufacturing capabilities. Transient transfection for vector production offers noteworthy flexibility for cell and gene therapy development. Pharmaceutical and biotechnology companies with the ability to achieve high-yielding clinical and commercial manufacturing of high-quality viral vectors using transient transfection are now offering their clients this flexibility combined with scalability and speed to market.

Moreover, the global pharmaceutical industry investment in research and development has increased over the years, Hence, with the increasing R&D expenditure, the market in the pharmaceutical industry is expected to attain a good growth over the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the global market studied. Research in the region, especially in the United States, is widely believed to be essential to the economic growth of North America, and the innovations derived from basic and applied research provide enormous benefits to society. For this reason, the federal government devotes a significant amount of funding towards biopharmaceutical products research. Hence, the US is expected to dominate the global market over the forecast period as well.

Key Topics Covered:

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Technological Advancements in Transfection

4.2.2 Increase in R&D Expenditure and Research Activities by Pharmaceutical and Biotech Companies

4.2.3 Rise in Demand for Synthetic Genes

4.3 Market Restraints

4.3.1 High Cost of Transfection Reagents

4.3.2 Selective Effectiveness and Certain Limitations of Transfection Reagents

4.4 Porter's Five Force Analysis

5 MARKET SEGMENTATION

5.1 By Product

5.1.1 Reagents

5.1.2 Equipment

5.2 By Method

5.2.1 Biochemical Methods

5.2.2 Physical Methods

5.2.3 Viral Methods

5.3 By End User

5.3.1 Pharmaceutical & Biotechnology Companies

5.3.2 Academics & Research Institutes

5.4 Geography

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/vr4czt


These press releases may also interest you

at 03:45
Phoenix Motor Inc. (the "Company"), a leading manufacturer of heavy-duty transit buses and electrification solutions provider for medium-duty vehicles, today announced it signed a waiver agreement with JAK Opportunities II LLC, one of the...

at 03:05
Vagaro, the leading international salon and spa software, and Jack Mead, award-winning hair stylist, salon owner, and educator, officially announced the release of their highly-anticipated Master Class series, delivering expert insights on using the...

at 02:30
Allied Market Research published a report, titled, "Pension Administration Software Market by Component (Solution and Services), Deployment Mode (On-Premise and Cloud), Type (Public Pension and Private Pension), End User (Employers, Pension Plan...

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...

at 02:00
Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood...

at 01:05
Teck Resources Limited (Teck) today announced its unaudited first quarter results for 2024. "All outstanding major construction at our QB operation was completed in the first quarter, including the shiploader and molybdenum plant, and we marked the...



News published on and distributed by: